key: cord-0698865-g7svvlvt
authors: Parsaeian, Seyedeh Fatemeh; Asadian, Fatemeh; Karimi-Zarchi, Mojgan; Setayesh, Sepideh; Javaheri, Atiyeh; Tabatabaie, Razieh Sadat; Dastgheib, Seyed Alireza; Golestanpour, Hossein; Neamatzadeh, Hossein
title: A Meta-Analysis for Association of XRCC3 rs861539, MTHFR rs1801133, IL-6 rs1800795, IL-12B rs3212227, TNF-α rs1800629, and TLR9 rs352140 Polymorphisms with Susceptibility to Cervical Carcinoma
date: 2021-11-03
journal: Asian Pac J Cancer Prev
DOI: 10.31557/apjcp.2021.22.11.3419
sha: 2c07083083527174622a81a357ef963bcf67333f
doc_id: 698865
cord_uid: g7svvlvt

BACKGROUND: In spite of substantial declines in both incidence and mortality rates in the past 50 years, cervical cancer remains one of the leading causes of cancer associated mortality among women globally. We performed this meta-analysis to explore the role of XRCC3 rs861539, MTHFR rs1801133, IL-6 rs1800795, IL-12B rs3212227, TNF-α rs1800629 and TLR9 rs352140 polymorphism with susceptibility to cervical carcinoma. METHODS: The search databases include PubMed, SciELO, MedRxiv, Web of Science, Scopus, Cochrane Library, China National Knowledge Infrastructure, and China Biology Medicine disc up to 30 June 2021. The language is limited to English and Chinese. The comparison between the polymorphisms and cervical cancer was assessed using pooled odds ratio (OR) and 95% confidence interval (CI). The data are statistically analyzed by Comprehensive Meta-Analysis (CMA) 2.0 software. RESULTS: A total of 59 studies including seven studies with 1,112 cases and 1,233 controls on XRCC3 rs861539, 14 studies with 2,694 cases and 3349 controls MTHFR rs1801133, four studies with 1,121 cases and 1,109 controls on IL-12B rs3212227, seven studies with 1,452 cases and 2,186 controls on IL-6 rs1800795, 20 studies with 4,781 cases and 4909 controls on TNF-α rs1800629, and seven studies with 1743 cases and 2292 controls on TLR9 rs352140 were included. There was a significant association between XRCC3 RS861539, TNF-α rs1800629, and IL-6 rs1800795 polymorphisms and an increased risk of cervical carcinoma in overall population. However, the MTHFR rs1801133, IL-12B rs3212227 and TLR9 rs352140 polymorphisms were not associated. CONCLUSION: The pooled analysis showed that XRCC3 RS861539, TNF-α rs1800629, and IL-6 rs1800795 were associated with cervical carcinoma susceptibility, but not MTHFR rs1801133, IL-12B rs3212227 and TLR9 rs352140 polymorphisms.

America and the Caribbean, and 245,000 in Asia (Arbyn et al., 2020) . Cervical cancer is driven by persistent infection with one of 15 carcinogenic human papillomavirus (HPV) types (Ghaemmaghamiet al., 2008; Chen et al., 2011) . However, the impact of HPV type and intratypic variants on patient outcomes is far less understood (Karimi- Zarchi et al., 2013; Baghestani et al., 2018; Rader et al., 2019) .

To date, the occurrence and development of cervical cancer is suggested to be associated with persistent HPV infection Zarchi et al., 2010; Pal and Kundu, 2020) . The DNA of HPV integrates into the host cell genome and disrupts the open reading frame and causes overexpression of E6 and E7 genes (Binesh et al., 2012; Soheili et al., 2016) . However, the specific molecular mechanisms and potential single gene require further studies. Familial based studies and evaluation of inherited genetic variations revealed that host genetic factors have a role in cervical cancer pathogenesis (Yang et al., 2020; Ahmadi et al., 2021) . Recently, a comprehensive review study showed that CDK1, CCNB1, ITGB1, FN1, MMP9 and STAT1 played different roles in the progression of cervical cancer through different signaling pathways (Sayad, Ahmadi, Nekouian, et al., 2020; Yi et al., 2020) . Moreover, studies have shown that cervical cancer has a heritable genetic component. However, as other complex disease, the identified loci only explain a minority of the risk of cervical cancer. This gap of the heritability explained by genetic markers genome-wide association studies and the heritability identified in familial studies has been termed as 'missing heritability' (Chen et al., 2016; Leo et al., 2017; Sayad, Ahmadi, Moradi, et al., 2020) . Thus, our understanding of the genetic basis of cervical cancer is still limited. In this meta-analysis, we explore the role of XRCC3 rs861539, MTHFR rs1801133, IL-6 rs1800795, IL-12B rs3212227, TNF-α rs1800629, and TLR9 rs352140 polymorphisms in susceptibility to cervical cancer.

We performed a comprehensive literature search on PubMed, Scopus, China National Knowledge Infrastructure, Wanfang, VIP Information Chinese Journal Service Platform, and China Biology Medicine disc, PubMed, EMBASE, Web of Science and the Cochrane Library, Google Scholar, Cochrane Library, EMBASE, Scientific Information Database (SID), WanFang, VIP, Chinese Biomedical Database (CBD), Scientific Electronic Library Online (SciELO), China National Knowledge Infrastructure (CNKI), IranDoc and Egyptian Knowledge Bank (EKB) Journals database to identify all relevant studies on the association of XRCC3 rs861539, MTHFR rs1801133, IL-6 rs1800795, IL-12B rs3212227, TNF-α rs1800629 and TLR9 rs352140 with cervical cancer up to 30th June 2021. The following terms were used in various combinations in this search: (''Uterine Cervical Neoplasm'' OR ''Cervix Cancer'' OR ''Cervical Cancer'' OR ''Cervical Neoplasm'' OR ''Cervical Carcinoma'' OR ''Squamous Cell Carcinoma'' OR ''Adenocarcinoma'') AND (''X-Ray Repair Cross Complementing 3'' OR ''XRCC3'' OR ''rs861539'' OR ''g.4880C>G'' OR ''c.-237C>G'' OR ''n.54-321G>C'' ) AND (''Methylene tetrahydrofolate reductase'' OR ' 'MTHFR'' OR ''677C>T'' OR ''rs1801133'' OR ''g.14783C>T'' OR ''c.788C>T'' OR ''p.Ala263Val'' OR ''p.Ala222Val'') AND (''Interleukin 12'' OR ''IL-12'' OR ''1188A>C'' OR ''rs3212227'' OR '' g.158742950T>G'' OR '' g.19532A>C'' OR '' c 

The search was carried out in English, Chinese and Persian. When overlapping data on the same cases were included in more than one publication, only the one with the larger sample size was selected. Moreover, the reference list of the retrieved studies and reviews manually checked to identify more potential eligible studies.

To obtain the papers, the following criteria should be met to include the papers in our study: 1) studies with case-control or cohort design; 2) studies reported original data; 3) studies appraised association of XRCC3 rs861539, MTHFR rs1801133, IL-6 rs1800795, IL-12B rs3212227, TNF-α rs1800629 and TLR9 rs352140 polymorphisms with cervical cancer; and 4) studies with available and sufficient data for calculating an odds ratio (OR) with 95% confidence interval (CI). The following exclusion criteria were also used: 1) studies on other polymorphism at XRCC3, MTHFR, IL-12B, IL-6, and TNF-α genes; 2) animal studies or in vitro studies; 3) studies with in sufficient data on genotype frequencies or which the number of genotypes and alleles could not be ascertained; 4) linkage studies; 5) family based studies including sibling, twins and trios-parents studies; 6) abstracts, case reports, commentaries, editorials, conference articles, reviews, proceedings and meta-analyses; and 7) duplicates studies or overlapping data.

Two authors reviewed and extracted necessary information independently in accordance with our inclusion criteria. For conflicting data, the authors carried out discussions until a consensus was reached. If they could not reach a consensus, disagreement was resolved by the third author who participated in the discussion. For each eligible study the following data was collected: first author name, year of publication, country of origin, ethnicity (Caucasian, Asian, African, Mixed populations), genotyping methods, sample size, allele and genotype frequency of XRCC3 rs861539, MTHFR rs1801133, IL-12B rs3212227, IL-6 rs1800795, TNF-α rs1800629 and TLR9 rs352140 polymorphisms in cervical cancer cases and controls, Minor Allele Frequency (MAFs) and Hardy-Weinberg equilibrium (HWE) in healthy controls. In this meta-analysis different case-control groups or cohorts in one publication were considered as independent total of 59 studies were included in this meta-analysis. There are seven studies with 1112 cases and 1233 controls on XRCC3 rs861539 (He et al., 2008; Xiao, 2009; Settheetham-Ishida et al., 2011; Djansugurova et al., 2013; Pérez et al., 2013; Al-Harbi et al., 2017) , 14 studies with 2694 cases and 3349 controls MTHFR rs1801133 (Lambropoulos et al., 2003; Sull et al., 2004; Kang et al., 2005; Zoodsma et al., 2005; Delgado-Enciso et al., 2006; Ma et al., 2006; Nandan et al., 2008; Shekari et al., 2008; Kohaar et al., 2010; Yang et al., 2011; Prasad and Wilkhoo, 2011; Tong et al., 2011; Mostowska et al., 2011; von Keyserling et al., 2011) , four studies with 1121 cases and 1109 controls on IL-12B rs3212227 (Chen et al., 2009; Do Carmo Vasconcelos De Carvalho et al., 2012; Roszak, Mostowska, et al., 2012) , seven studies with 1452 cases and 2186 controls on IL-6 rs1800795 (Nogueira De Souza et al., 2006; Gangwar et al., 2009; Grimm et al., 2011; Shi et al., 2013; de Lima Júnior et al., 2016; Pu et al., 2016; Zidi et al., 2017) , 20 studies with 4,781 cases and 4909 controls on TNF-α rs1800629 (Stanczuk et al., 2019; Jang et al., 2001; Calhoun et al., 2002; Gostout et al., 2003; Deshpande et al., 2005; Duarte et al., 2005; Govan et al., 2006; Kohaar et al., 2007; Singh et al., 2009; Zu et al., 2010; Ivansson et al., 2010; Zuo et al., 2011; Wang et al., 2011 Wang et al., , 2012 Badano et al., 2012; Barbisan et al., 2012; Sousa et al., 2014; Roszak et al., 2015; Zidi et al., 2015) and seven studies with 1743 cases and 2292 controls on TLR9 rs352140 (Pandey et al., 2011; Lai et al., 2013; Bi, 2014; Zidi et al., 2016; Jin et al., 2017) . The details of included studies were shown in Tables 1 and 2. All those 22 studies were reported in English and Chinese. Among those 59 studies, 31 studies were from Asian populations, 18 studies from Caucasian populations, five studies from African populations, and five studies were from mixed populations. The studies have been carried out in China, Thailand, Argentina, Kazakhstan, Brazil, Saudi Arabia, Greece, Korea, Netherlands, Mexico, India, Poland, Germany, Austria, Tunisia, Zimbabwe, USA, South Africa, Sweden, and Portugal. The sample size of cases ranged from 21 to 636, while the sample size of controls ranged from 73 to 800 in the controls. Eight different methods including AS-PCR, PCR-RFLP, Direct Sequencing, SnapShot, TaqMan, LDR-PCR, ARMS-PCR, qRT-PCR and HMR were used to genotyping those polymorphisms. Hardy-Weinberg equilibrium (HWE) test was calculated for all publications and P<0.05 was considered as a departure from HWE (Table 1) .

The summary for the association of XRCC3 RS861539 polymorphism with cervical cancer risk are shown in Table 3 . Pooled data revealed that XRCC3 RS861539 polymorphism was significantly associated with susceptibility to cervical cancer under the heterozygote genetic model (TC vs. CC: OR = 1.00, 95% CI 1.066-1.585, p = 0.009). Moreover, stratified analysis by ethnicity revealed that the polymorphisms was significantly associated with cervical cancer in Asian women under three genetic models, i.e., allele (T vs. C: OR= 1.302, studies. We did not define any minimum sample size to include in this meta-analysis. The ''mixed'' group means mixed or unknown populations. If more than one study was published by the same author(s) using repeated or overlapped data, the studies with the largest sample size or the most recently published study was included to the meta-analysis. If selected articles did not reported necessary data the corresponding authors was contacted by email to request the missing data.

The comparison between the XRCC3 rs861539, MTHFR rs1801133, IL-6 rs1800795, IL-12B rs3212227, TNF-α rs1800629 and TLR9 rs352140 polymorphism and cervical cancer was assessed using pooled odds ratio (OR) and 95% confidence interval (CI). The pooled data were calculated under five genetic models, i.e., allele (B vs. A), homozygote (BB vs. AA), heterozygote (BA vs. BB), dominant (BB+BA vs. AA) and recessive (BB vs. BA+AA), in which a ''A'' denotes a major allele; ''B'' denotes a minor allele. The χ 2 test and I 2 statistics were used to assess whether there was between-study heterogeneity, in which P >.10 and I 2 < 50% could be considered that there was no statistical heterogeneity between the research results. The fixed effect model was selected for data consolidation; P ≤.10 and I 2 ≥50% could be considered that there was statistical heterogeneity between the research results, and a random effect model was used for data consolidation. If there was significant heterogeneity among studies, the random effects model (DerSimonian and Laird) was used; otherwise, the fixedeffects model (Mantel and Haenszel) was acceptable. The Hardy-Weinberg equilibrium of the control group was evaluated using the χ 2 test, and the expected and actual genotype frequencies of the control group were compared. In this meta-analysis, P-values of ≤.05 were considered statistically significant (Azadi-Yazdi et al., 2017; Mirjalili et al., 2019; Dastgheib et al., 2020) . In addition, the sensitivity analysis was performed by excluding HWE-violating studies. Potential publication bias was evaluated using the Egger's linear regression test and Begg's quantitative test. The asymmetric plot of Egger's test and the P-value of Begg's test less than 0.05 were considered a significant publication bias. If there was evidence of publication bias (P<0.05), trim and fill method was applied to adjust for the effect of publication bias (Jafari et al., 2020) . All statistical analyses were performed using Comprehensive Meta-Analysis (CMA) Software version 2.0 (Biostat, Englewood, USA). All tests were two-sided, and the P< 0.05 was considered statistically significant.

The flowchart of selection of studies and reasons for exclusion is presented in Figure 1 . There were 1,013 articles relevant to our search words and 395 duplicated studies were excluded. Then, 207 studies removed after reading titles and abstracts. Following the inclusion exclusion criteria 352 studies were excluded. Finally, a 

The summary for the association of TNF-α rs1800629 polymorphism with cervical cancer risk are shown in Table 3 . Pooled data from all eligible studies indicated that the TNF-α rs1800629 polymorphism was associated with cervical cancer risk in overall population under four genetic models i.e., allele (A vs. G: OR = 1.277, 95% CI = 1.104-1.477, P = 0.001), homozygote (AA vs. GG: OR = 1.333, 95% CI = 1.062-1.674, P = 0.013), heterozygote (AG vs. GG: OR = 1.307, 95% CI = 1.064-1.605, P = 0.011), and dominant (AA+AG vs. GG: OR = 1.324, 95% CI = 1.104-1.587, P = 0.002). The subgroup analysis by ethnicity also showed that this polymorphism was associated with cervical cancer in Caucasian women under three genetic models i.e., allele (A vs. G, OR = 1.242, 95% CI = 1.043-1.478, P = 0.015); homozygote (AA vs. GG, OR = 1.586, 95% CI = 1.147-2.193, P = 0.005), and recessive (AA vs. AG+GG, OR = 1.569, 95% CI = 1.137-2.165, P = 0.006) and in African women under two genetic models i.e., heterozygote (AG vs. GG, OR = 1.670, 95% CI = 1.228-2.270, P = 0.001) and dominant (AA+AG vs. GG, OR = 1.453, 95% CI = 1.111-1.902, P = 0.006), but not in Asian women.

The summary for the association of MTHFR rs1801133 polymorphism with cervical cancer risk are shown in Table 3 . Pooled results showed that the MTHFR rs1801133 polymorphism was not associated with cervical cancer in overall population and by ethnicity.

The summary for the association of IL-12B rs3212227 polymorphism with cervical cancer risk are shown in Table 4 . Pooled data showed that the IL-12B rs3212227 polymorphism was not associated with cervical cancer globally. Stratified analysis by ethnicity revealed that this polymorphism was associated with cervical cancer in Asian women under two genetic models i.e., heterozygote (CA vs. AA: OR = 1.349, 95% CI 1.032-1.762, p=0.028) and dominant (CC+CA vs. AA: OR = 1.340, 95% CI 1.041-1.725, p =0.023).

The summary for the association of IL-6 rs1800795 polymorphism with cervical cancer risk are shown in Table 4 . Pooled data from all eligible studies showed that the IL-6 rs1800795 polymorphism was significantly associated with cervical cancer risk under four genetic models, i.e., allele (C vs. G: OR = 1.294, 95% CI 1.071-1.564, p= 0.007), homozygote (CC vs. GG: OR = 1.633, 95% CI 1.059-2.520, p= 0.027), dominant (CC+CG vs. GG: OR = 1.312, 95% CI 1.048-1.643, p= 0.018) and recessive (CC vs. CG+GG: OR = 1.592, 95% CI 1.268-1.999, p≤0.001). Moreover, subgroup analysis by 

The summary for the association of TLR9 rs352140 polymorphism with cervical cancer risk are shown in Table 4 . Pooled results showed that the TLR9 rs352140 polymorphism was not associated with cervical cancer in overall population and by ethnicity.

In the current meta-analysis the χ 2 test and I 2 statistics were used for assessing the heterogeneity of the included studies. Results indicate that there was statistical heterogeneity for XRCC3 rs861539, MTHFR rs1801133, IL-6 rs1800795, IL-12B rs3212227, TNF-α rs1800629, and TLR9 rs352140 polymorphisms under most genetic models. Thus, the random effect model was used for evaluating the pooled OR and 95% CI for those models. Subgroup analyses showed that ethnicity of participants Table 4 . Summary Risk Estimates for Association of IL-6 rs1800795, TNF-α rs1800629 and TLR9 rs352140 Polymorphisms with Cervical Cancer Risk might contribute to part of heterogeneity.

The process of performing a meta-analysis involves a sequence of decisions and it is important to perform a sensitivity analysis in order to assess the impact of different decisions on pooled data. Thus, a sensitivity analysis was carried out by excluding a single study in turn on pooled ORs. The results showed that no individual study had an influence on the pooled OR all involved polymorphisms at XRCC3 rs861539, MTHFR rs1801133, IL-6 rs1800795, IL-12B rs3212227, TNF-α rs1800629, and TLR9 rs352140 polymorphisms, suggesting the stability of our findings. Moreover, excluding HWE deviated studies suggested that there were no independent studies that significantly influenced our pooled data.

Begg's funnel plot and Egger's test were used for evaluating publication bias. As shown in Tables 3 and  4 , the Egger's test results showed that there was no publication bias for the XRCC3 rs861539, MTHFR rs1801133, IL-6 rs1800795, IL-12B rs3212227, TNF-α rs1800629, and TLR9 rs352140 polymorphisms under all five genetic models. Moreover, Begg's funnel did not statistically revealed a significant publication bias in any of the models for all involved polymorphisms. Thus, the publication bias tests revealed that our pooled ORs were reliable.

Genetic factors have been shown to influence the susceptibility of patients to various diseases and have attracted increasing attention (Motamedi et al., 2012; Mazaheri et al., 2014; Kabiri Rad et al., 2018) . Several efforts have been made to identify the genetic susceptibility factors underlying development of cervical cancer. However, only a few polymorphisms have shown consistency among studies. In this meta-analysis, the association of XRCC3 rs861539, MTHFR rs1801133, IL-6 rs1800795, IL-12B rs3212227, TNF-α rs1800629 and TLR9 rs352140 polymorphisms with susceptibility to cervical carcinoma was assessed by including all relevant studies. Yuan et al., (2021) in a meta-analysis based on 15 studies with 5,740 cases and 9,931 controls revealed that there was no significant association between the XRCC3 Thr241Met and the risk of gynecological malignancies. However, their subgroup analysis by ethnicity showed that XRCC3 Thr241Met was associated with an increased risk of gynecological malignancies in Asians. Moreover, their stratified analysis by cancer type indicated that XRCC3 Thr241Met associated with cervical cancer in Asians (CT vs. CC: OR=1.50, 95%CI=1.04-2.14; TT vs. CC: OR=3.14, 95%CI=1.38-7.14; CT+TT vs. CC: OR=1.64, 95% CI=1.17-2.31). Abbas et al., (2010) in a case-control study with 260 cervical cancer cases and 265 controls evaluated the association of XRCC1+399A/G, XRCC2+31467G/A and XRCC3+18067C/T polymorphisms with cervical cancer in Indian women. Their results showed that XRCC2+31479G/A and XRCC3+18067C/T polymorphisms were not associated with cervical cancer. However, they showed that he XRCC1+399A/G is linked with cervical cancer in the Indian population. Al-Harbi et al., (2017) in a study among 232 cervical cancer cases and 313 control subjects evaluated the association of CDKN1A C31A, ATM G1853A, HDM2 T309G, TGFB1 T10C, XRCC1 G399A, and XRCC3 C241T with cervical cancer among Saudi Arabian women. They showed that the TGFB1 T10C and XRCC1 G399A polymorphisms were associated with cervical cancer risk.

Our pooled results showed that the MTHFR rs1801133 polymorphism was not associated with cervical cancer in overall population and by ethnicity. Silva et al., (2019) reported that there were no differences in the genotypic and allelic distribution of MTHFR C677T polymorphism between remission (with the presence of pre-neoplastic lesions) and Persistence (with the presence of pre-neoplastic lesions). The same authors, in another study showed that MTHFR C677T polymorphism was not associated with cervical cancer and HPV infection (Silva et al., 2019) . However, Sohrabi et al., in a case-control study evaluated the association of MTHFR A1298C and C677T variants among in 50 cervical intraepithelial neoplasia cases, 98 HPV-positive subjects and 47 non-cancerous/non-HPV patients as healthy controls. Their results showed that MTHFR 1298 CC is more likely to be a potential risk factor for HPV-cervical cancer progression (Sohrabi et al., 2020) . Zhou et al., (2020) indicated that the MTHFR rs4846048 enhanced the risk of cervical cancer through association with miR-522. Gong et al., (2018) reported that MTHFR C677T polymorphism was not associated with the risk of cervical cancer or cervical intra-epithelial neoplasia, while, the MTHFR A1298C polymorphism could increase the risk of both cervical cancer and cervical intra-epithelial neoplasia.

In the current study pooled data indicated that the TNF-α rs1800629 polymorphism was associated with cervical cancer risk. Wang et al., (2012) in meta-analysis based 27 studies showed that both TNF-α -238 and -308 G/A polymorphisms could be used to identity individual with elevated susceptibility to cervical cancer in by ethnicity (Bi, 2014) . Behboodi et al., (2021) in a study among 153 Iranian cervical cancer cases and 292 free cancer subjects demonstrated that TNF-α rs1800629 was associated with increased level and risk of developing cervical cancer. However, Duvlis et al., (2020) reported that TNF-a-238G/A and TNF-a-308 G/T polymorphisms were not associated with the risk of HPV associated cervical intraepithelial lesions or cervical cancer cases in Macedonian women compared to controls. Moreover, Traore et al., (2020) revealed that TNF-308 G/A or IL18-607C/A polymorphisms were not associated with HPV infection among Burkina Faso women.

Pooled data from all eligible studies showed that the IL-6 rs1800795 polymorphism was significantly associated with cervical cancer risk in overall population and among Asian women. Similarly, Duan et al., (2018) in a meta-analysis based on 7 studies showed that the IL-6 rs1800795 polymorphism is associated with risk of cervical cancer in overall. Pu et al., (2016) in a study with 360 cervical cancer cases and 728 healthy subjects showed that this polymorphism is risk factor for cervical cancer development in Chinese women. de Souza et al., (2006) in a case-control study with 56 cases and 253 controls evaluated the association of IL-6 rs1800795 polymorphism with cervical cancer in a Brazilian population. In 2017, Zidi et al., (2017) in a case-control study evaluated the effects of six different genetic variants atIL-6 with risk of cervical cancer. The study revealed that the IL-6 rs1800795 polymorphism has a has a protective role in cervical cancer development in Tunisian women. de Lima Júnior et al., (2016) revealed that the IL-6 rs1800795 polymorphism was not associated with HPV infection and healthy controls in in Brazilian women. The current meta-analysis data showed that the IL-12B rs3212227 genetic variant was not associated with susceptibility to cervical cancer, while; stratified analysis showed that this polymorphism was associated with cervical cancer risk among Asian women. Zheng et al., (2017) in a metaanalysis based on 33 articles with 10,587 cancer cases and 12,040 healthy subjects assessed the genetic association of IL-12B rs3212227 with cancer risk. Their pooled data indicated that IL-12B rs3212227 polymorphism was associated with cancer risk in overall. However, subgroup analysis by cancer type showed that IL-12B rs3212227 was not associated with cervical cancer. In 2016, Chang et al., (2015) in a meta-analysis based on 5 studies with 2552 cervical cases and 2232 healthy subjects showed that this polymorphism did not associate with risk of cervical cancer. In 2012, de Carvalho et al., found that the IL-12B rs3212227 variant has a protective role in development of cervical cancer in Brazilian women (Do Carmo Vasconcelos De Carvalho et al., 2012) . Similarly, Han et al., (2008) found that IL-12B rs3212227 did not associate with cervical cancer risk in Korean population. However, showed that this polymorphism was associated with increased risk of cervical cancer among polish women.

The current meta-analysis data showed that TLR9 rs352140 was not associated with susceptibility to cervical cancer. Nath et al., (2020) in a study showed that TLR4/9 polymorphisms are associated with increased HPV16/18 infection susceptibility and cervical squamous cell carcinoma risk among the women of Jharkhand state. In another study in India showed the TLR4 and TLR9 polymorphisms and haplotypes with hrHPV infection and cervical cancer risk (Pandey et al., 2019) . Martínez-Campos et al., (2017) in a case-control study revealed that TLR9 rs187084 is a risk factor for HPV infection, squamous intraepithelial cervical lesion, and uterine cervical neoplasm in Mexican female population. Jin et al., (2017) also evaluated the association of some variants at Toll-like receptors gene with cervical cancer among 420 Chinese cervical cancer patients and 842 controls. Their results showed that mutant alleles of TLR2 rs3775290, TLR4 rs7873784, and TLR9 rs352140 were associated with increased cervical cancer risk. Similarly, Yang et al., (2020) in meta-analysis based on eleven studies indicated that the TLR9 rs187084 and rs352140 polymorphisms may contribute to development of cervical cancer, but not TLR2-196 to -174 del/ins polymorphism.

In summary, our pooled data indicated that the XRCC3 RS861539, TNF-α rs1800629, and IL-6 rs1800795 genetic variants were associated with susceptibility to cervical cancer globally. However, the MTHFR rs1801133, IL-12B rs3212227 and TLR9 rs352140 variants were not associated. Larger and more rigorous studies among different ethnicities are needed to further evaluate these associations with cervical cancer. 

Genetic polymorphisms in DNA repair genes and their association with cervical cancer

Expression of Angiogenesis-related Genes in a Group of Iranian Cases of Breast Cancer

Genetic predisposition to cervical cancer and the association with XRCC1 and TGFB1 polymorphisms

The Risk and Prevalence of COVID-19 Infection in Colorectal Cancer Patients: a Systematic Review and Meta-analysis

Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis

Effects of Dietary Approach to Stop Hypertension diet on androgens, antioxidant status and body composition in overweight and obese women with polycystic ovary syndrome: a randomised controlled trial

Analysis of TNFα promoter SNPs and the risk of cervical cancer in urban populations of Posadas (Misiones, Argentina)

Comparison cure rate models by DIC criteria in Breast Cancer data

TNF-α and IL-10 promoter polymorphisms, HPV infection, and cervical cancer risk

Association of a variant in the tumor necrosis factor alpha gene with risk of cervical cancer

Study on TLRs polymorphisms and cervical cancer susceptibility

Primary malignant lymphoma of the uterine cervix

Host genetic polymorphism analysis in cervical cancer

IFN-gamma and IL-12B polymorphisms in women with cervical intraepithellial neoplasia caused by human papillomavirus

Association of interleukin-12 gene polymorphisms with cancer susceptibility: a meta-analysis

Pooled analysis of genome-wide association studies of cervical intraepithelial neoplasia 3 (CIN3) identifies a new susceptibility locus

Interactions of IL-12A and IL-12B polymorphisms on the risk of cervical cancer in Chinese women

Genetic susceptibility of cervical cancer

Association of plasminogen activator inhibitor-1 4G5G Polymorphism with risk of diabetic nephropathy and retinopathy: a systematic review and meta-analysis

The effect of MTHFR polymorphisms, pregnancy and first intercourse on cervical cancer in a population from the Northeastern Mexico

TNF-α promoter polymorphisms and susceptibility to human papillomavirus 16-associated cervical cancer

The determination of genetic markers of age-related cancer pathologies in populations from Kazakhstan

Association of IL-6 -174G>C (rs1800795) polymorphism with cervical cancer susceptibility

G-308A TNF-α polymorphism is associated with an increased risk of invasive cervical cancer

Association of TNF-a (rs361525 and rs1800629) with susceptibility to cervical intraepithelial lesion and cervical carcinoma in women from Republic of North Macedonia

Association of interleukin-6 -174G>C promoter polymorphism with risk of cervical cancer

Uterine sarcoma: Clinicopathological characteristics, treatment and outcome in Iran

Surgical management of primary vulvar lymphangioma circumscriptum and postradiation: Case Series and Review of Literature

Association between the hOGG1 1245C>G (rs1052133) polymorphism and susceptibility to colorectal cancer: a Meta-analysis Based on 7010 Cases and 10,674 Controls

The association between MTHFR polymorphism and cervical cancer

TAP1, TAP2, and HLA-DR2 alleles are predictors of cervical cancer risk

The allelic distribution of -308 Tumor Necrosis Factor-alpha gene polymorphism in South African women with cervical cancer and control women

Genetic variations of interleukin-1 and -6 genes and risk of cervical intraepithelial neoplasia

Association of the s1799724 and rs1800629 Polymorphisms of the TNF-α Gene with Susceptibility to Cervical Cancer: a Systematic Review and Meta-Analysis based on 24 Case-Control Studies

Interleukin-12 p40 gene (IL12B) polymorphisms and the risk of cervical caner in Korean women

Susceptibility of XRCC3, XPD, and XPG genetic variants to cervical carcinoma

Interaction of immunological genes on chromosome 2q33 and IFNG in susceptibility to cervical cancer

Association of PAI-1 rs1799889 polymorphism with susceptibility to ischemic stroke: a Huge Meta-Analysis based on 44 Studies

The -238 tumor necrosis factor-alpha promoter polymorphism is associated with decreased susceptibility to cancers

Cancer and Coronavirus Disease (COVID-19): Comorbidity, Mechanical Ventilation, and Death Risk

Association of toll-like receptor gene polymorphisms and its interaction with HPV infection in determining the susceptibility of cervical cancer in Chinese Han population

Relative expression of PBMC MicroRNA-133a analysis in patients receiving Warfarin after mechanical heart valve replacement

Polymorphism in folate-and methionine-metabolizing enzyme and aberrant CpG island hypermethylation in uterine cervical cancer

A comparison of the effect of levonorgestrel IUD with oral medroxyprogesterone acetate on abnormal uterine bleeding with simple endometrial hyperplasia and fertility preservation

Analysis of 4 single-nucleotide polymorphisms in relation to cervical dysplasia and cancer development using a high-throughput ligation-detection reaction procedure

Homocysteine levels are associated with cervical cancer independent of methylene tetrahydrofolate reductase gene (MTHFR) polymorphisms in Indian population

TNFalpha-308G/A polymorphism as a risk factor for HPV associated cervical cancer in Indian population

Toll-like receptor 9 (TLR9) gene polymorphisms associated with increased susceptibility of human papillomavirus-16 infection in patients with cervical cancer

Methylenetetrahydrofolate reductase polymorphism C677T is not associated to the risk of cervical dysplasia

Defining the genetic susceptibility to cervical neoplasia-A genome-wide association study

Influence of IL-6, IL-8, and TGF-β1 gene polymorphisms on the risk of human papillomavirus-infection in women from Pernambuco, Brazil

Variant genotypes of CDKN1A and CDKN1B are associated with an increased risk of breast cancer in Chinese women

TLR9 gene polymorphism −1486T/C (Rs187084) is associated with uterine cervical neoplasm in Mexican female population

Molecullar and biochemical effect of alcohlic extract of alpinia galanga on rat spermatogenesis process

The value of ultrasonography in determining pupillary light reflex in patients with traumatic ocular injuries; a Letter to Editor

Folate and choline metabolism gene variants and development of uterine cervical carcinoma

Tamoxifen resistance and CYP2D6 copy numbers in breast cancer patients

Allelic variations in 5, 10-methylenetetrahydrofolate reductase gene and susceptibility to cervical cancer in Indian women

Polymorphisms and haplotypes of TLR4, TLR9 and CYP1A1 genes possibly interfere with high-risk human papillomavirus infection and cervical cancer susceptibility in Jharkhand

Interleukin-6 polymorphisms and the risk of cervical cancer

Human papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for

Association of TLR4 and TLR9 polymorphisms and haplotypes with cervical cancer susceptibility

Evaluation of Toll-like receptors 3 (c.1377C/T) and 9 (G2848A) gene polymorphisms in cervical cancer susceptibility

XRCC2 R188H (rs3218536), XRCC3 T241M (rs861539) and R243H (rs77381814) Single Nucleotide polymorphisms in cervical cancer risk

Association of the functional polymorphism C677T in the methylenetetrahydrofolate reductase gene with colorectal, thyroid, breast, ovarian, and cervical cancers

Polymorphisms of the interleukin 6 gene and additional gene-gene interaction contribute to cervical cancer susceptibility in Eastern Chinese women

Genetic variations in human papillomavirus and cervical cancer outcomes

Involvement of toll-like receptor 9 polymorphism in cervical cancer development

TNF-α -308 G/A as a risk marker of cervical cancer progression in the Polish population

Contribution of IL12A and IL12B polymorphisms to the risk of cervical cancer

A meta-analysis on diagnostic accuracy of serum HLA-G level in breast cancer

Epidemiological and pathological characteristics of post-surgical cases of invasive breast cancer among ethnicities of Iran in 2018: A single center cross-sectional study

Genetic risk of DNA repair gene polymorphisms (XRCC1 and XRCC3) for high risk human papillomavirus negative cervical cancer in Northeast Thailand

Impact of methylenetetrahydrofolate reductase (MTHFR) codon (677) and methionine synthase (MS) codon (2756) on risk of cervical carcinogenesis in North Indian population

Polymorphisms of the Interleukin 6 gene contribute to cervical cancer susceptibility in Eastern Chinese women

The role of HPV-induced epigenetic changes in cervical carcinogenesis (Review)

Lack of association between methylenetetrahydrofolate reductase C677T polymorphism, HPV infection and cervical This work is licensed under a Creative Commons Attribution

intraepithelial neoplasia in Brazilian women

Association of TNFA (−308G>A) and IL-10 (−819C>T) promoter polymorphisms with risk of cervical cancer

Determination of the physical status (Episomal/Integral) of HPV by qPCR in esophageal squamous cell carcinoma

The impact of MTHFR 1298 A > C and 677 C > T gene polymorphisms as susceptibility risk factors in cervical intraepithelial neoplasia related to HPV and sexually transmitted infections

Tumour necrosis factor alpha 308 G/A is a risk marker for the progression from high-grade lesions to invasive cervical cancer

Polymorphism at the -308-promoter position of the tumor necrosis factor-alpha (TNF-alpha) gene and cervical cancer

The effect of methylenetetrahydrofolate reductase polymorphism C677T on cervical cancer in Korean women

Common polymorphisms in methylenetetrahydrofolate reductase gene are associated with risks of cervical intraepithelial neoplasia and cervical cancer in women with low serum folate and vitamin B12

Association of TNF-α-308G/A and IL-18 Polymorphisms with risk of HPV infection among sexually active women in Burkina Faso

TNF-Alpha rs1800629 polymorphism is not associated with HPV infection or cervical cancer in the Chinese population

Association between cytokine gene polymorphisms and cervical cancer in a Chinese population

The association between XRCC3 gene polymorphism and cervical cancer risk

The relationship of the TLR9 and TLR2 genetic polymorphisms with cervical cancer risk: a Meta-Analysis of Case-Control Studies

Study on the correlation between polymorphism of MTHFR gene and the pathogenesis of cervical cancer. Mat Child Health Care China

Comprehensive gene and pathway analysis of cervical cancer progression

Association between XRCC3 Thr241Met polymorphism and risk of gynecological malignancies: A meta-analysis

Evaluation of cervical cancer risk-factors in women referred to Yazd-Iran hospitals from 2002 to 2009

Role of interleukin-12 gene polymorphisms in the onset risk of cancer: A metaanalysis

The SNP rs4846048 of MTHFR enhances the cervical cancer risk through association with miR-522: A preliminary report

Evaluation of Toll-Like Receptors 2/3/4/9 Gene Polymorphisms in Cervical Cancer Evolution

Relationships between common and novel interleukin-6 gene polymorphisms and risk of cervical cancer: a Case-Control Study

Tumor Necrosis Factor Alpha (-238 / -308) and TNFRII-VNTR (-322) Polymorphisms as Genetic Biomarkers of Susceptibility to Develop Cervical Cancer Among Tunisians

Methylenetetrahydrofolate reductase (MTHFR) and susceptibility for (pre)neoplastic cervical disease

A preliminary study of TNFa gene 308 single nucleotide polymorphism with cervical cancer risk and HPV subtype infection in southern Xinjiang Uygur patients

Association of TNF-α gene promoter polymorphisms with susceptibility of cervical cancer in Southwest China

None.

This article does not contain any studies with human participants or animals performed by any of the authors.

Not applicable for this manuscript.

The datasets generated during and/or analyzed during this study are available from the corresponding author on reasonable request.

The authors declare that they have no conflict of interest.